All In Biotech

NDA 021283 · Novartis

Diovan

Valsartan · Oral · Angiotensin 2 Receptor Blocker

Last checked: Nov 19, 2026Latest source record: Jul 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

Jul 18, 2001

Approved uses

6

Original approval plus efficacy supplements

Registered trials

499

141 Phase 3, 34 recruiting

FAERS reports

105,697

80,579 serious, 9,601 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue Diovan as soon as possible. (5.1) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. (5.1) WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue Diovan as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 )

What it is approved for

From the label in effect Aug 11, 2026.

Diovan is an angiotensin II receptor blocker (ARB) indicated for: Hypertension , to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) Heart failure (NYHA class II-IV), to reduce hospitalization for heart failure in adults ( 1.2 ) Post-myocardial infarction , for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Diovan ® is indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with Diovan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic...

Mechanism: Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Diovan (valsartan) blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • DIOVAN · VALSARTAN 320MG · TABLET, ORAL · Prescription · TE AB
  • DIOVAN · VALSARTAN 80MG · TABLET, ORAL · Prescription · TE AB
  • DIOVAN · VALSARTAN 40MG · TABLET, ORAL · Prescription · TE AB
  • DIOVAN · VALSARTAN 160MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Valsartan" as an intervention, any sponsor and status, largest first.

All 499 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective6,427
  • fatigue5,691
  • dizziness5,453
  • dyspnoea5,406
  • nausea5,312
  • diarrhoea4,778
  • headache4,671
  • hypertension4,393
  • blood pressure increased4,307
  • pain3,901
  • fall3,690
  • asthenia3,686

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,626
20052,193
20062,550
20072,616
20082,697
20093,818
20104,607
20115,852
20125,748
20134,926
20145,417
20156,320
20166,084
20175,890
20188,380
20196,939
20205,330
20214,715
20224,408
20233,921
20244,235
20254,198
20263,216

Recalls

1 FDA enforcement reports for this application.

  • Aug 4, 2026 · Class II · Ongoing

    Failed Dissolution Specifications

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Diovan (Valsartan)

2024 spending

$20.7M

Beneficiaries

5,891

25,913 claims

Per beneficiary

$3,521

$9.72 per unit

View as table
YearSpending
2020$30,473,828
2021$25,650,355
2022$23,452,329
2023$23,819,426
2024$20,741,930

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,232 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.